Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

(2020) Dmitriy Zamarin et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial

(2020) Elizabeth K. Lee et al.   GYNECOLOGIC ONCOLOGY

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer

(2020) Emese Zsiros et al.   JAMA Oncology

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

(2019) Mary L. Disis et al.   JAMA Oncology

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study

(2019) U A Matulonis et al.   ANNALS OF ONCOLOGY

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

(2019) Panagiotis A. Konstantinopoulos et al.   JAMA Oncology

Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer

(2019) Ying L. Liu et al.   GYNECOLOGIC ONCOLOGY

Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy

(2018) Junjie Wu et al.   CANCER LETTERS

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance

(2018) Kristina Lindemann et al.   GYNECOLOGIC ONCOLOGY

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

(2018) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028

(2018) Andrea Varga et al.   GYNECOLOGIC ONCOLOGY

Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles

(2018) Shannon Grabosch et al.   ONCOGENE

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper

(2017) Thomas J. Herzog et al.   GYNECOLOGIC ONCOLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma

(2016) S. Bo hm et al.   CLINICAL CANCER RESEARCH

Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy

(2016) Charlotte S. Lo et al.   CLINICAL CANCER RESEARCH

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer

(2016) Ronald D. Alvarez et al.   GYNECOLOGIC ONCOLOGY

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

(2016) Kyle C. Strickland et al.   Oncotarget

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient preferences in advanced or recurrent ovarian cancer

(2014) Laura J. Havrilesky et al.   CANCER

Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics

(2014) S. V. Hato et al.   CLINICAL CANCER RESEARCH

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

(2014) Sandro Pignata et al.   LANCET ONCOLOGY

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes

(2012) Katy Milne et al.   Journal of Translational Medicine

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

(2011) W. Joost Lesterhuis et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of Frequently Used Chemotherapeutic Drugs on Cytotoxic Activity of Human Cytotoxic T-lymphocytes

(2009) Laszlo Markasz et al.   JOURNAL OF IMMUNOTHERAPY

Individual patient data analysis to assess modifications to the RECIST criteria

(2008) Jan Bogaerts et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

(2007) William E. Winter et al.   JOURNAL OF CLINICAL ONCOLOGY